Revenue and Adjusted EBITDA improvements of 6.4% and 9.5%, respectively from the prior quarter Reduced debt by $4.6 million ...

MA's rising earnings outlook and global momentum fuel optimism, but premium valuation and mounting regulatory risks temper ...

Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...